- Home
- FTNT vs TAK Comparison
FTNT vs TAK Comparison
Compare FTNT & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTNT | TAK |
|---|---|---|
| Founded | 2000 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1B | 56.6B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTNT | TAK |
|---|---|---|
| Price | $84.13 | $16.74 |
| Analyst Decision | Hold | |
| Analyst Count | 25 | 0 |
| Target Price | ★ $85.71 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 2.8M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | ★ 7.08 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $6,799,600,000.00 | N/A |
| Revenue This Year | $14.02 | $0.16 |
| Revenue Next Year | $10.51 | $1.22 |
| P/E Ratio | ★ $35.63 | $41.25 |
| Revenue Growth | ★ 14.17 | N/A |
| 52 Week Low | $70.12 | $12.99 |
| 52 Week High | $109.32 | $18.90 |
Technical Indicators
Market Signals| Indicator | FTNT | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 38.26 |
| Support Level | $83.56 | $14.83 |
| Resistance Level | $86.88 | $18.86 |
| Average True Range (ATR) | 2.58 | 0.19 |
| MACD | 0.37 | -0.12 |
| Stochastic Oscillator | 71.88 | 29.31 |
Price Performance
Historical ComparisonAbout FTNT Fortinet Inc.
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.